SCHEMBL30420464

SCHEMBL30420464

Cc1nc(-c2cccc(Cl)c2)oc1-c1ccc(=O)[nH]n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.50
GPR119 Q8TDV5 1/20 0.45
IKBKB O14920 1/20 0.43
CYP1A2 P05177 1/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
AHR P35869 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
GUSB P08236 1/20 0.39
AKR1B1 P15121 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25180877 1.00 NOTUM (0.50) NOTUMGPR119IKBKBCYP1A2TP53
SCHEMBL24039007 0.79 NPC1 (0.57) NOTUMGPR119CYP1A2TP53NPC1
SCHEMBL31256752 0.79 NPC1 (0.57) NOTUMGPR119CYP1A2TP53NPC1
SCHEMBL4048920 0.77 CYP1A2 (0.62) NOTUMGPR119CYP1A2AHRKMT2A
Bromide SCHEMBL11739258 0.76 CYP1A2 (0.61) NOTUMGPR119CYP1A2AHRKMT2A
SCHEMBL30419948 0.74 MAPT (0.63) NOTUMTP53MAPTNPC1RAB9A
SCHEMBL25418543 0.74 MAPT (0.63) NOTUMTP53MAPTNPC1RAB9A
SCHEMBL5536101 0.72 NPC1 (0.53) NOTUMIKBKBCYP1A2TP53MAPT
SCHEMBL8889786 0.70 CYP1A2 (0.45) NOTUMGPR119CYP1A2AHRKMT2A
SCHEMBL25180859 0.69 MAPT (0.54) NOTUMIKBKBTP53MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336609-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-10-10 US disclosed
EP-4433473-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-09-25 EP disclosed
WO-2023091606-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336609-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A NOTUM 3831/4885GPR119 3611/4885IKBKB 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.